Voyageur Pharmaceuticals Ltd VM

Calgary, Alberta--(Newsfile Corp. - September 24, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, announces that it proposes to settle debts in the aggregate amount of $192,300 (the "Debt") through the issuance of common shares of the Company ("Common Shares") at a deemed price of $0.155 per Common Share, being the closing price of the Common Shares..

CALGARY, ALBERTA - September 9, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is ple...

CALGARY, ALBERTA - August 10, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleas...

Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization and liquidity services to the...

Fluor Corporation (NYSE:FLR) reached substantial completion on the Chicago Transit Authority Red and Purple Line Modernization project, the largest capital project in CTA history. The company has been engaged by Voyageur Pharmaceuticals to conduct studies on a North American based pharmaceutical supply chain. Both developments expand Fluor's activity across urban transit infrastructure and integrated pharmaceutical supply chains. Fluor enters this news cycle with its shares at $49.45 and a...

CALGARY, ALBERTA - June 23, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased...

CALGARY, ALBERTA - June 18, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased...

CALGARY, AB - June 10, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the "Company" or "Voyageur") announces the submission of a Multi-Year Area-Based ("MYAB") Notice of Work ("NoW") application to the British Columbia Ministry of M...

CALGARY, ALBERTA, CANADA - June 5, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to announc...

CALGARY, AB - March 16, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a pharmaceutical company focused on developing barium and iodine contrast media drugs for medical imaging, is ple...

CALGARY, ALBERTA - February 23, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media drugs, is p...

CALGARY, AB - November 7, 2025 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to anno...